Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Stephen Hoffman

General Practice Mc Connellsburg, PA Doctor of Osteopathy

NPI 1568482867 CMS profile 1034189

525 Fulton Dr, Mc Connellsburg, PA 17233

Open in the dashboard

General payments

$1,075

71 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Stephen Hoffman of Mc Connellsburg, PA is reported in the CMS Open Payments database as having received $1,075 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $15 1
2022 General $208 12
2021 General $100 6
2020 General $180 13
2019 General $556 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Hoffman
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Stephen Hoffman were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Stephen Hoffman General Practice median Middle half National median
2019 $556 $107 $37–$285 $163
2020 $180 $75 $25–$213 $114
2021 $100 $93 $30–$272 $132
2022 $208 $103 $36–$279 $149
2023 $15 $106 $34–$276 $160
2024 $17 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $420 30 payments
  2. Lilly USA, LLC $110 8 payments
  3. AstraZeneca Pharmaceuticals LP $109 5 payments
  4. Amarin Pharma Inc. $50 3 payments
  5. Currax Pharmaceuticals LLC $49 4 payments
  6. Amgen Inc. $47 3 payments
  7. Sanofi-Aventis U.S. LLC $44 1 payment
  8. Novartis Pharmaceuticals Corporation $43 3 payments
  9. Pfizer Inc. $42 3 payments
  10. GlaxoSmithKline, LLC. $38 3 payments
  11. Other $123 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,075 71 payments
Products named General payments · program years 2019–2024
  1. Ozempic $275 19 payments
  2. RYBELSUS $145 9 payments
  3. FARXIGA $109 5 payments
  4. TRULICITY $95 7 payments
  5. JARDIANCE $85 6 payments
  6. Saxenda $84 7 payments
  7. BASAGLAR $69 5 payments
  8. Tresiba $61 4 payments
  9. Victoza $61 4 payments
  10. Xultophy 100/3.6 $61 4 payments
  11. Other $578 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$2,313

Medicare's payments for the services billed

Medicare patients

107

Average age 72

Services billed

154

77 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 41%
Ischemic heart disease 29%
COPD 19%
Heart failure 15%
Depression 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record